Prognostic value of haemoglobin drop in patients with acute coronary syndromes

Eur J Clin Invest. 2021 Dec;51(12):e13670. doi: 10.1111/eci.13670. Epub 2021 Sep 20.

Abstract

Background: The prognostic value of in-hospital haemoglobin drop in patients with acute coronary syndrome (ACS) undergoing invasive therapy remains insufficiently investigated.

Materials and methods: This observational study included 3838 patients with ACS with admission and in-hospital nadir haemoglobin values available. Haemoglobin drop was defined as a positive difference between admission and nadir haemoglobin values. The primary endpoint was one-year all-cause mortality.

Results: In-hospital haemoglobin drop occurred in 3142 patients (82%). Patients were categorized into 4 groups: no haemoglobin drop (n = 696 patients), <3 g/dl haemoglobin drop (n = 2703 patients), 3 to <5 g/dl haemoglobin drop (n = 344 patients) and ≥5 g/dl haemoglobin drop (n = 95 patients). The primary endpoint occurred in 156 patients: 17 patients (2.5%) in the group with no haemoglobin drop, 81 patients (3.0%) in the group with <3g/dl haemoglobin drop, 37 patients (10.9%) in the group with 3 to <5 g/dl haemoglobin drop and 21 patients (22.2%) in the group with ≥5 g/dl haemoglobin (adjusted hazard ratio [HR] = 1.30, 95% confidence interval 1.17 to 1.45; p < .001 for one g/dl haemoglobin drop). The association of haemoglobin drop with one-year mortality remained significant after exclusion of patients with in-hospital overt bleeding (adjusted HR = 1.27 [1.11-1.46]; p < .001 for one g/dl haemoglobin drop). The lowest haemoglobin drop associated with mortality was 1.23 g/dl in all patients (HR = 1.03 [1.02-1.04]) and 1.13 g/dl in patients without overt bleeding (HR = 1.03 [1.01-1.04]).

Conclusions: In patients with ACS, in-hospital haemoglobin drop was associated with higher risk of one-year mortality even in the absence of overt bleeding.

Keywords: acute coronary syndrome; bleeding; haemoglobin; mortality.

Publication types

  • Observational Study

MeSH terms

  • Acute Coronary Syndrome / blood*
  • Acute Coronary Syndrome / therapy
  • Aged
  • Aspirin / therapeutic use
  • Dual Anti-Platelet Therapy*
  • Female
  • Hemoglobins / metabolism*
  • Humans
  • Male
  • Middle Aged
  • Mortality*
  • Percutaneous Coronary Intervention*
  • Platelet Aggregation Inhibitors / therapeutic use
  • Postoperative Hemorrhage / blood*
  • Postoperative Hemorrhage / chemically induced
  • Prasugrel Hydrochloride / therapeutic use
  • Prognosis
  • Proportional Hazards Models
  • Randomized Controlled Trials as Topic
  • Ticagrelor / therapeutic use

Substances

  • Hemoglobins
  • Platelet Aggregation Inhibitors
  • Prasugrel Hydrochloride
  • Ticagrelor
  • Aspirin